Physician profile
Amy B Cole
NPI 1275623084
$14,761.87
in general payments reported to CMS, 2019-2025
34 companies · $2,938 in 2025
The $2,938 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $496 · 2021: $1,193 · 2022: $2,212 · 2023: $3,355 · 2024: $3,210 · 2025: $2,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,313 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,312.88 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,816.74 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,265.99 | 2019-2025 | |
| Genzyme Corporation | $1,159.86 | 2019-2025 | |
| Janssen Biotech, INC. | $1,094.81 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $899.82 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Pfizer INC. | $865.71 | 2019-2025 | |
| Incyte Corporation | $858.58 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $842.94 | 2019-2025 | Adbry |
| Dermavant Sciences, INC. | $669.92 | 2022-2024 | Vtama |
| Lilly USA, LLC | $577.06 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $525.21 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $523.23 | 2019-2025 | Ilumya, Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $453.80 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Arcutis Biotherapeutics, INC. | $402.71 | 2023-2025 | Zoryve |
| Ucb, INC. | $401.90 | 2020-2025 | Bimzelx, Cimzia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.69 | 2022-2025 | Spevigo |
| Almirall LLC | $331.80 | 2019-2025 | Klisyri |
| Organon LLC | $268.06 | 2025 | Vtama |
| Revance Therapeutics, INC. | $250.09 | 2024-2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $222.17 | 2021-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $216.35 | 2019-2023 | |
| Celgene Corporation | $209.70 | 2019 | |
| Amgen INC. | $179.29 | 2020-2025 | Otezla, Otezla |
| Medimetriks Pharmaceuticals, INC. | $86.34 | 2024-2025 | |
| Sebela Pharmaceuticals INC. | $57.90 | 2021-2023 | Naftin |
| Allergan, INC. | $56.06 | 2021 | |
| Vyne Pharmaceuticals INC. | $51.62 | 2021 | |
| Journey Medical Corporation | $24.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.39 | 2019 | |
| Strata Skin Sciences, INC. | $19.87 | 2025 | Xtrac |
| Epi Health, LLC | $19.40 | 2019 | |
| Dermira, INC. | $19.23 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.17 | 2019 | |
| Kestra Medical Technology Services, INC. | $16.36 | 2024 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.